Immune checkpoint blockade therapy based on PD-1/PD-L1 restores T-cell function by preventing the binding of PD-1 or PD-L1 antibodies during ICI treatment, and promotes anti-tumor immunity. This evidence concerns the gene CD274 and neoplasm.